Hepatitis C Information Central


Discover the latest news about Hepatitis C infection, diagnosis, symptoms and treatments here at Hepatitis-Central.com.

Hep C information

News, Updates and Commentary

Free Newsletter
Hepatitis C Newsletter
We value your privacy. We will not rent your email to anyone.

HEPATITIS NEWS
The top stories compiled from over 5,500 sources, updated every 15 minutes

77 More Hepatitis Cases Linked to Clinic
Seventy-seven more people that were treated at a Las Vegas outpatient clinic have been diagnosed with hepatitis C, health officials said. Authorities can't say for sure how the 77 people were infected, said Brian Labus, senior epidemiologist with the

Officials: 77 more hepatitis cases may trace to clinic
AM ET LAS VEGAS (AP) - Health officials in Las Vegas say 77 more people who were treated at an outpatient clinic have been diagnosed with hepatitis C. Authorities can't say for sure how the 77 people were infected. Officials say they know each was

More hepatitis cases may trace to clinic
AM CDT LAS VEGAS - Seventy-seven more people have been diagnosed with hepatitis C that they may have contracted during treatment at a Las Vegas outpatient clinic, public health administrators said Thursday.The 77 people are among about 400 former


UPDATES AND COMMENTARY RSS Feed

Highly Effective Against HCV Genotype 1
When tested on people with Hepatitis C genotype 1, R7128 proved to be an effective addition to combination therapy after just four weeks' time. In addition to its anti-viral effect, polymerase inhibitor R7128 received good marks for safety and minimal...

Investigational Drug Beats Standard Therapy in Hepatitis C Study
A Phase IIa trial investigating triple combination therapy with PEGASYS, COPEGUS and Roche's investigational drug R1626, demonstrated a higher response rate than traditional combination therapy alone. While R1626's effectiveness and high barrier to resistance makes it a top Hepatitis C...

Hepatitis C Complications Helped by Maintenance Interferon
A four-year study confirms that low-dosage maintenance interferon therapy prevents disease progression in those with portal hypertension or cirrhosis from Hepatitis C....

PROGRAF [tacrolimus]

Purpose:

PROGRAF is prescribed to prevent or treat organ rejection in people who have received liver transplants. It is used for long-term (perhaps lifetime) immunosuppression.

How to take:

  • Capsules 1 mg (milligram) and 5 mg. If PROGRAF is taken twice daily, doses should be 12 hours apart. Either oral or IV PROGRAF may be given immediately after transplantation.
  • The transplant team will determine the dosage appropriate for each patient based on weight, blood levels, other laboratory tests, and the possible side effects of PROGRAF.
  • PROGRAF should be taken 1 hour before meals or 2 hours after meals.

Precautions:

  • Initially, the patient should also be taking corticosteroids, such as prednisone and/or azathioprine, when he takes PROGRAF.
  • The patient is likely to have frequent lab tests during the first few months to monitor the effectiveness and side effects of PROGRAF.
  • On a day when PROGRAF level is to be measured, the patient should not take his morning PROGRAF dose until after his blood has been drawn.
  • Store PROGRAF at room temperature (59º to 86º F).
  • PROGRAF may interact with some commonly used medications. Check with the transplant team before starting any new medications.
  • The benefits of taking this medication if a patient is pregnant or breast feeding must be weighed against the potential hazards to her, her fetus, or her infant. A woman who thinks she is pregnan should consult the transplant team immediately.

Principal side effect:

These include, but are not limited to, headaches, nausea, diarrhea, tremor, high blood sugar, high potassium levels, decreased magnesium levels, abnormal kidney function, hair loss, sleep disturbances, and numbness and tingling of hands or feet.

Conversion:

The transplant team may decide to give the patient PROGRAF instead of cyclosporine, or vice versa, because of side effects or rejection. If this occurs, the patient should follow the instructions of the transplant team.

  Hep C information

Information at this website is for educational purposes only; statements about products and health conditions
have not been evaluated by the U.S. Food & Drug Administration.

©1994-2008 Hepatitis-Central.com
Updated 09 May 2008